The a2 Milk Company (ASX: A2M) today, 19 November 2026, provided an update on its China Infant Milk Formula (IMF) recovery and its financial outlook for the 2027 financial year. The a2 Milk Company is a global nutrition company that commercialises a variety of dairy products, including infant milk formula, containing only the A2 type of beta-casein protein. The company anticipates FY27 revenue and EBITDA growth, driven by product innovation, new markets, and continued momentum in other nutritional and liquid milk segments.
Previous disruptions included shortfalls in China label IMF product in 4Q26, impacting market availability and leading to customer switching. English label IMF offtake was also affected by a USA label IMF recall in May 2026. The company’s China IMF recovery plan is progressing, with estimated China label offtake now at approximately 50% of pre-supply chain disruption levels, up from around 40% in August 2026. Total IMF sales are projected to be broadly similar to FY26, with gradual recovery expected over FY27, supported by new China label products, an updated a2 Platinum™ product, and increased marketing.
Financially, The a2 Milk Company expects mid-single digit percentage revenue growth for FY27. However, first-half FY27 revenue is anticipated to be slightly lower than the prior corresponding period. The underlying EBITDA margin is forecast at approximately 15%, with 1H27 materially down on 1H26, indicating Group revenue and EBITDA will be significantly weighted to the second half of FY27. One-off transformation costs are projected at approximately $15 million in FY27, with no further costs expected in FY28. The company also noted the NZD’s devaluation, with net earnings uplift offset by hedge losses.